TRAIL-Induced Apoptosis in Cancer Therapy

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has emerged as a compelling therapeutic agent owing to its capacity to trigger programmed cell death specifically in malignant cells while sparing normal tissues. Engagement of TRAIL with its functional death receptors, DR4 and DR5, induces receptor trimerisation and formation of the death-inducing signalling complex, leading to activation of initiator caspase-8 and downstream effector caspases. Despite promising preclinical activity, early clinical trials revealed limited efficacy due to rapid clearance, suboptimal agonistic potency and intrinsic or acquired resistance mechanisms in diverse tumour types. Recent advances address these challenges through optimisation of ligand structure and delivery, incorporation of sensitising agents to overcome apoptotic blocks and integration with physical modalities to enhance receptor clustering. Collectively, these strategies seek to reinstate robust extrinsic apoptotic signalling, broaden tumour specificity and translate TRAIL-based therapies into effective clinical regimens.

Research from Nature Portfolio

Innovative engineering of TRAIL has focused on extending systemic exposure and enhancing trimer stability. A trimer-tag fusion format incorporates a collagen-derived C-propeptide at the TRAIL C-terminus, yielding a covalently linked homotrimer that exhibits superior receptor binding kinetics and markedly prolonged half-life in vivo. This design confers enhanced antitumour activity in xenograft models at doses tolerable in preclinical safety studies, directly correlating systemic exposure to therapeutic efficacy. Such structural refinement underscores the importance of persistent receptor engagement and provides a platform for next-generation death-receptor agonists.

TRAIL-Induced Apoptosis in Cancer Therapy publication trend

The graph below shows the total number of articles in trail-induced apoptosis in cancer therapy across all publications each year (not limited to Nature Index journals).

Technical terms

TRAIL: A cytokine belonging to the TNF superfamily that selectively induces apoptosis in cancer cells.

Death receptors (DR4/DR5): Cell-surface receptors with cytoplasmic death domains that recruit adaptor proteins to initiate extrinsic apoptosis.

Decoy receptors: Receptor homologues lacking functional death domains that bind TRAIL without transducing apoptotic signals.

Caspase-8: An initiator protease activated at the death-inducing signalling complex, which triggers downstream effector caspases.

Sensitiser: An agent or modality that lowers the apoptotic threshold of tumour cells, restoring or enhancing responsiveness to TRAIL.

Piezo1: A mechanosensitive ion channel that transduces mechanical stimuli into calcium influx, augmenting apoptosis signalling.

References

1. Applying Ultrasound to Mechanically and Noninvasively Sensitize Prostate Tumors to TRAIL‐Mediated Apoptosis. Advanced Science (2025).
2. Getting TRAIL back on track for cancer therapy. Cell Death & Differentiation (2014).
3. Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells. Frontiers in Oncology (2015).
4. The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. Frontiers in Molecular Biosciences (2021).
5. Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo. Scientific Reports (2017).